Sherpa Healthcare Fund II GP

Sherpa targets growth-stage companies, primarily Series B and later rounds in the biopharma, medical device, and digital health sectors. This stage aligns with the capital-intensive clinical trial and regulatory approval phases where specialized underwriting is critical.

The firm does not publicly list excluded sub-sectors. However, given its typical focus on regulated therapeutics and devices, it is less likely to participate in pure healthcare services or general wellness businesses that lack a strong FDA regulatory pathway. This inference is based on the scientific complexity required for its typical underwriting.

Sherpa Healthcare Fund II GP acts as the general partner for the firm's second dedicated healthcare fund, indicating a sequential, institutionalized fundraising structure. Details on Fund I's performance or the precise vintage and size of Fund II remain undisclosed in public records.

The specific named principals and investment committee members for this general partner entity are not identified in the available public record. Life-science funds typically rely on partners with advanced scientific degrees (MD or PhD) and industry operating experience, though this remains unconfirmed for Sherpa.

The firm is known to execute direct equity investments in portfolio companies requiring growth capital. There is no public evidence of an active fund-of-funds commitment strategy or secondary market participation for this specific vehicle.